Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Naseptin Nasal Cream

{email} Notify me of changes to this product

emc account functionality

Sign in or register for an emc account to use this functionality and much more:

  • Get the latest updates to your inbox

    Receive email notifications when chosen products are updated

  • Stay up to date with document change history

    Get full access to document change history

  • Similar product search

    Use active ingredient, company or ATC code

  • Save your regular searches

    Simple access to search enquiries every time you need them

  • Favourite products you use most often

    Helps you find products you use regularly as fast as possible

Active Ingredient:
chlorhexidine dihydrochloride , neomycin sulfate
Company:  
Alliance Pharmaceuticals See contact details
ATC code: 
D06AX
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Safety Alert
{arrow_left}
{arrow_right}
{healthcare_pro_orange} For Healthcare Professionals

Naseptin® Nasal Cream (neomycin sulphate, chlorhexidine dihydrochloride) – Formulation Update

Naseptin® Nasal Cream (neomycin sulphate, chlorhexidine dihydrochloride) underwent a formulation change in 2023, the excipient Arachis oil (peanut oil) was removed.

The last batches of the original formulation containing Arachis oil expired on 31st October 2025. As of 1st November 2025, we expect that only the revised formulation without Arachis oil remains on the market. There should no longer be any batches of the original formulation of Naseptin® Nasal Cream containing Arachis oil in the supply chain.

There are no listed contraindications regarding patients with peanut or soya allergy for Naseptin Nasal Cream. Nonetheless, Healthcare professionals should continue to review patient allergy status, in line with the approved Product Information as part of routine prescribing and dispensing practices.

For further information, please contact the Medical Information department at Alliance Pharmaceuticals Ltd: call +44 (0)1249 466 966 or email [email protected].

Alliance Pharmaceuticals
Company image
Address
Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone
+44 (0)1249 466 966
Fax
+44 (0)1249 466 977
WWW
http://www.alliancepharma.co.uk
Medical Information e-mail
[email protected]